Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22324118 | 0.79 | CHRM2 (0.40) | KCNH2OPRK1THRBCHRM2CHRM4 | |
| SCHEMBL16237040 | 0.79 | CHRM2 (0.40) | KCNH2OPRK1THRBCHRM2CHRM4 | |
| SCHEMBL7684110 | 0.79 | CHRM2 (0.38) | KCNH2OPRK1CHRM2CHRM4CHRM5 | |
| SCHEMBL7684150 | 0.77 | OPRK1 (0.33) | KCNH2OPRK1OPRM1 | |
| SCHEMBL7688348 | 0.75 | CHRM2 (0.36) | KCNH2OPRK1THRBCHRM2CHRM4 | |
| SCHEMBL22323735 | 0.75 | CHRM2 (0.40) | KCNH2OPRK1CHRM2CHRM4CHRM5 | |
| SCHEMBL16237411 | 0.75 | CHRM2 (0.40) | KCNH2OPRK1CHRM2CHRM4CHRM5 | |
| SCHEMBL16249858 | 0.74 | THRB (0.38) | KCNH2OPRK1THRBCHRM2CHRM4 | |
| SCHEMBL16240502 | 0.73 | NR1H2 (0.41) | KCNH2OPRK1THRBCHRM2CHRM4 | |
| SCHEMBL16237439 | 0.73 | CHRM2 (0.35) | THRBCHRM2CHRM4CHRM5SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020061913-A1 | Bicyclic amine derivatives | SYNGENTA LIMITED (GB) | 2002-05-23 | — | — | US | disclosed |
| US-6291474-B1 | COMBATING AND CONTROLLING INSECT, ACARINE OR NEMATODE PESTS | ZENECA LIMITED (GB) | 2001-09-18 | — | — | US | disclosed |
| US-6177442-B1 | INSECTICIDES; PESTICIDES; MITICIDES; NEMATOCIDES | ZENECA LIMITED (GB) | 2001-01-23 | — | — | US | disclosed |
| US-5968947-A | INSECTICIDES, ACARICIDES, NEMATOCIDES | ZENECA LIMITED (GB) | 1999-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061913-A1 | Bicyclic amine derivatives | ADRA1D, TAAR1, ADRA1A | KCNH2 1046/4885OPRK1 523/4885THRB 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.